Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2014-04-28 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2013年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2013 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the dividend distribution plan approved at the 2013 Annual General Meeting, including dividend amounts, record dates, ex-dividend dates, and payment methods. The document is relatively short (1669 characters) and primarily announces the implementation of the dividend distribution rather than providing a full annual report or financial statements. It references the shareholder meeting resolution and provides contact information for inquiries. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. It is not a full Annual Report (10-K) or Earnings Release (ER), nor is it a Proxy Solicitation or Voting Results announcement. Therefore, the correct classification is DIV with high confidence.
2014-04-28 Chinese
2014年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 First Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, shareholder information, and management's discussion of financial results for the first quarter of 2014. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2014
2014-04-21 Chinese
2014年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 First Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data for the first quarter of 2014, including revenue, net profit, earnings per share, cash flow, and changes in shareholders. It also includes management's discussion of significant changes in financial statement items, shareholder commitments, and a forecast for the next half-year period. The document length is 8878 characters, which is substantial and contains actual financial statements and analysis. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2014
2014-04-21 Chinese
2013年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of the 2013 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and results. The document does not contain the actual annual report or financial statements but rather confirms the validity of the AGM process and voting outcomes. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2014-04-18 Chinese
2013年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2013 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the meeting attendance, voting results on various proposals including the 2013 annual report, profit distribution plan, and appointment of auditors. The document is a formal announcement of the voting results from the AGM, not the full AGM materials or the annual report itself. The length is short (1969 characters) and it primarily reports the outcomes of shareholder votes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2014-04-18 Chinese
关于使用自有闲置资金投资银行理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the use of its own idle funds to invest in bank wealth management products. It details the investment amounts, terms, risk disclosures, and approvals from the board, independent directors, and supervisory board. The document does not contain financial statements or detailed financial performance data but rather describes a specific financing/investment activity and related corporate governance approvals. It is not a full financial report, earnings release, or regulatory certification. The content fits best under Capital/Financing Update (CAP) as it concerns the company's capital deployment and investment activities.
2014-04-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.